ARA-290

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is ARA-290?

ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin (EPO). Unlike EPO itself, ARA-290 was specifically designed to activate the tissue-protective receptor — the EPO receptor/CD131 (β-common receptor) heterodimer — without stimulating red blood cell production through the classical homodimeric EPO receptor. This separation of tissue-protective from haematopoietic effects was the central design objective.[1][2]

ARA-290 has progressed further through clinical development than most research peptides, with completed phase 2 trials in diabetic neuropathy and diabetic macular oedema. The peptide represents a targeted approach to harnessing EPO’s cytoprotective signalling without the dangerous side effects (thrombosis, hypertension) associated with EPO’s erythropoietic activity.[3]

Compound Profile

What Does ARA-290 Actually Do?

ARA-290 research demonstrates tissue-protective and anti-inflammatory effects across multiple organ systems without affecting red blood cell production. The peptide activates the innate repair receptor (IRR) — the EPO receptor/CD131 heterodimer — triggering cytoprotective signalling cascades that reduce apoptosis, inflammation, and tissue damage.[1][2]

In clinical studies, ARA-290 has shown effects on small nerve fibre regeneration in type 2 diabetes patients with neuropathy, improvement in corneal nerve fibre density, and reduction of neuropathic pain scores. A phase 2 trial in diabetic macular oedema demonstrated anti-inflammatory effects on retinal pathology.[3][4]

How ARA-290 Works

ARA-290’s mechanism centres on selective activation of the innate repair receptor (IRR), a heterodimeric receptor complex composed of the EPO receptor and CD131 (β-common receptor). This receptor is expressed on neurons, endothelial cells, cardiomyocytes, and immune cells, but is distinct from the homodimeric EPO receptor that drives erythropoiesis.[1][2]

Anti-apoptotic signalling: IRR activation triggers JAK2/STAT5 and PI3K/Akt survival pathways, promoting cell survival under stress conditions including ischaemia, inflammation, and metabolic injury. ARA-290 has been shown to protect against cisplatin-induced nephrotoxicity through these pathways.[5]

Anti-inflammatory modulation: ARA-290 modulates innate immune responses, reducing pro-inflammatory cytokine production and shifting macrophage polarisation toward reparative phenotypes. This immune modulation has been demonstrated in models of autoimmune uveitis and haemolytic-uraemic syndrome.[6][7]

Neuroprotective effects: In cerebral ischaemia models, ARA-290 mediated brain tissue protection through β-common receptor-dependent pathways, reducing infarct volume and improving neurological outcomes.[8]

Recovery & Sleep Context

ARA-290’s tissue-protective profile is directly relevant to recovery research. The peptide’s ability to protect tissues from ischaemic, inflammatory, and metabolic insults — while promoting reparative immune responses — represents a recovery-supportive mechanism at the cellular level.[1][2]

Clinical evidence in diabetic neuropathy patients showed ARA-290 promoted small nerve fibre regeneration, suggesting active tissue repair rather than merely damage prevention. This regenerative capacity distinguishes ARA-290 from purely protective agents and places it in the tissue recovery domain.[3]

Preclinical cardiac research demonstrated ARA-290 reduced cardiac inflammation and attenuated age-associated declines in heart function, suggesting recovery-relevant effects in cardiovascular tissue.[9] Direct evidence linking ARA-290 to sleep or systemic recovery metrics is absent. Compare with BPC-157 and TB-500 for related tissue repair profiles, or see the Recovery & Sleep goal page.

Injury & Tissue Support Context

The injury and tissue support context is arguably ARA-290’s strongest research domain. The peptide was designed specifically to harness EPO’s tissue-protective signalling — a pathway evolved to protect tissues from injury-related damage.[1]

Preclinical models have demonstrated ARA-290’s protective effects across diverse injury types: cerebral ischaemia, cisplatin nephrotoxicity, haemolytic-uraemic syndrome, autoimmune uveitis, and diabetic neuropathy. The breadth of tissue responsiveness reflects the wide expression pattern of the EPO/CD131 heteroreceptor across organ systems.[5][6][7][8]

Traumatic brain injury research has identified erythropoietin derivatives including ARA-290 as candidates for phase-targeted neuroprotection, where tissue-protective effects without haematopoietic stimulation address a key safety concern in TBI management.[10] See the Injury & Tissue Support goal page for broader context.

ARA-290 Benefits

• Selective tissue protection: Activates the protective EPO/CD131 receptor without stimulating erythropoiesis, avoiding thrombotic and hypertensive risks associated with EPO.[1][2]
• Clinical trial evidence: Phase 2 trials in diabetic neuropathy and macular oedema provide human efficacy and safety data — more clinical evidence than most research peptides.[3][4]
• Nerve fibre regeneration: Clinical evidence demonstrating small nerve fibre regrowth in diabetic neuropathy patients suggests genuine regenerative capacity.[3]
• Anti-inflammatory immune modulation: Shifts immune responses toward reparative phenotypes, addressing the inflammatory component of tissue injury.[6][7]
• Multi-organ protection: Preclinical evidence spans neural, cardiac, renal, retinal, and skeletal tissue — reflecting broad IRR expression.[5][8][9]

ARA-290 Side Effects

ARA-290 has a more established safety profile than most research peptides, thanks to phase 2 clinical trial data:

• No haematopoietic effects: Clinical studies confirmed ARA-290 does not affect haemoglobin, haematocrit, or red blood cell counts — validating the selective receptor targeting design.[3]
• Injection site reactions: Mild, transient injection site reactions were the most commonly reported adverse events in clinical trials.
• Generally well-tolerated: Phase 2 trials reported adverse event rates comparable to placebo, with no serious adverse events attributed to ARA-290.
• Limited long-term data: Clinical trial durations were relatively short (weeks to months). Long-term safety of sustained IRR activation remains uncharacterised.

Half-Life

ARA-290 has a plasma half-life of approximately 2–3 minutes after intravenous administration, reflecting rapid renal clearance of this small peptide. Despite the short circulating half-life, subcutaneous administration (used in clinical trials) produces a longer effective exposure through depot absorption, and downstream biological effects persist beyond peptide clearance through sustained intracellular signalling cascades.

Clinical dosing protocols have used daily subcutaneous injection, consistent with a pharmacodynamic duration of action exceeding the pharmacokinetic half-life.

Limits of Current Evidence

• No phase 3 trials completed: While phase 2 data is promising, ARA-290 has not completed the large-scale trials required for regulatory approval in any jurisdiction.
• Limited indication scope: Clinical data exists primarily for diabetic neuropathy and diabetic macular oedema. Extrapolation to other conditions relies on preclinical models.
• Commercial development uncertainty: The clinical development pathway for ARA-290 has been prolonged, raising questions about commercial viability and ongoing investment.
• Dose optimisation incomplete: Optimal dosing regimens for different indications have not been fully established.
• Receptor selectivity assumptions: While designed for IRR selectivity, complete absence of effects through other receptors has not been exhaustively demonstrated.

Verdict

ARA-290 represents one of the more pharmacologically sophisticated peptides in the research pipeline — a rationally designed molecule targeting a specific receptor heterodimer to separate tissue protection from erythropoiesis. The scientific premise is elegant, the preclinical data is extensive, and the phase 2 clinical results provide genuine human evidence for nerve fibre regeneration and tissue-protective effects.

The challenge is translational momentum. Despite promising early clinical data, ARA-290 has not progressed to phase 3 trials, and the commercial development pathway remains unclear. For researchers interested in EPO-derived cytoprotection, ARA-290 provides a well-characterised tool with unusually strong clinical validation for a research peptide — but its ultimate therapeutic role depends on continued clinical development.

FAQ

What is ARA-290?

ARA-290 (also known as cibinetide) is an 11-amino acid synthetic peptide derived from the structure of erythropoietin. It selectively activates the tissue-protective EPO receptor/CD131 heterodimer without stimulating red blood cell production, providing cytoprotective and anti-inflammatory effects.

What is cibinetide used for?

Cibinetide (ARA-290) has been investigated in phase 2 clinical trials for diabetic neuropathy and diabetic macular oedema. Preclinical research has explored its potential in cerebral ischaemia, cardiac injury, kidney protection, and autoimmune conditions. It is not currently approved for any clinical indication.

How does ARA-290 differ from EPO?

EPO activates the homodimeric EPO receptor, stimulating red blood cell production along with tissue protection. ARA-290 selectively activates only the EPO/CD131 heterodimer (innate repair receptor), providing tissue protection without erythropoietic stimulation. This avoids EPO’s risks of thrombosis and hypertension.

Has ARA-290 been tested in humans?

Yes. ARA-290 has completed phase 2 clinical trials in diabetic neuropathy (showing small nerve fibre regeneration) and diabetic macular oedema (showing anti-inflammatory retinal effects). It has not yet progressed to phase 3 trials.

What are ARA-290 side effects?

In phase 2 clinical trials, ARA-290 was generally well-tolerated with adverse event rates comparable to placebo. Mild injection site reactions were the most commonly reported side effect. Importantly, ARA-290 did not affect blood cell counts, confirming its selectivity for tissue-protective rather than haematopoietic pathways.

Is ARA-290 the same as EPO?

No. ARA-290 is a short 11-amino acid peptide derived from a specific region (helix B surface) of the much larger EPO molecule. It targets a different receptor complex and does not stimulate red blood cell production. ARA-290 was designed to capture EPO’s tissue-protective benefits without its haematopoietic effects.

References

1. Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med. 2012. PMID: 22354215
2. Liu G, et al. The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury. Int Immunopharmacol. 2024. PMID: 38943972
3. Rendell MS. The time to develop treatments for diabetic neuropathy. Expert Opin Investig Drugs. 2021. PMID: 33423557
4. Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. J Clin Med. 2020. PMID: 32674280
5. Ghassemi-Barghi N, et al. Mechanistic Approach for Protective Effect of ARA290 against Cisplatin-Induced Nephrotoxicity. Inflammation. 2023. PMID: 36085231
6. Merzbach S, et al. Anti-Inflammatory Effects of Clarstatin on Experimental Autoimmune Uveitis in Mice. Invest Ophthalmol Vis Sci. 2025. PMID: 39775697
7. Dennhardt S, et al. Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome. Front Immunol. 2022. PMID: 36211426
8. Wang RL, et al. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemia. CNS Neurosci Ther. 2024. PMID: 38488446
9. Winicki NM, et al. A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function. Front Cardiovasc Med. 2022. PMID: 36741836
10. Sun Y, et al. Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy. Front Neurol. 2025. PMID: 41659975